Report Fraud About Us What We Do

Valsartan Recall Consider The Consumer

Consumer News

Valsartan Recall: Patients Taking Valsartan at Risk of Developing Cancer

Valsartan Recall – Who’s Affected?

The popular blood pressure medication Valsartan, the generic drug for Diovan, is now under scrutiny for allegations of possibly causing cancer as the drug may have been contaminated at manufacturing plants in China and India.

The contamination problem was only discovered recently but consumers expressed concerns of patients using the drug for several years to develop an increased risk of Valsartan cancer. A lawsuit investigation is now underway to examine potential claims that patients, who took valsartan and later developed unexpected complications like tumors and cancer, can seek. This applies to patients who took Valsartan between 2014 and 2018.

Did you or a loved suffer from cancer damage after taking Valsartan? If yes, feel free to contact us today!

Contact Us

Why Was Valsartan Recalled?

Valsartan is a class of hypertension medication known as angiotensin II receptor agonists that work to reduce blood vessel constriction and let blood flow more freely. The Food and Drug Administration (FDA) approved Valsartan as a treatment for high blood pressure in adults and children aged six and up and to treat heart failure and reduce the risk of death in patients who recently had a heart attack.

Common side effects of the drug are:

  • Dizziness
  • Head congestion
  • Drowsiness
  • Nausea
  • Vomiting
  • Diarrhea
  • Cough

Separate FDA investigations of pharmaceutical manufacturing plants in Linhai, China, and Hyderabad, India reported that ingredients in Valsartan have been contaminated with a potentially carcinogenic substance because of changes in the manufacturing process for sartan drugs. The changes were made to reduce waste and make production more efficient but have inadvertently produced an unexpected chemical reaction that caused the formation of NDMA, or N-Nitrosodimethylamine, which is part of a class of chemicals known as “nitrosamines.”

NDMA can cause kidney cancer and other malignancies in sufficient quantities. Valsartan recalls were issued since the problem was first discovered in 2018.

Contact UsEditor’s note on the Valsartan Recall:

This piece is written about the recent Valsartan Recall.  If you believe that what was alleged leading to the Valsartan Recall has affected you, please don’t hesitate to reach out to us. We’d be happy to help you take a step in the right direction, fight this issue, and better enable you to join in on any potential consumer class action. If interested, please send an email to Outreach@ConsiderTheConsumer.com, find us on Twitter or Facebook, or even connect with us directly on our website! We look forward to hearing from you all.

Similarly, please check out our current list of Class Actions and Class Action Investigations, here.

Interested in articles like these? Become a subscriber below!

Interested in posts like these? Stay up to date with our newsletter!

No thoughts on “Valsartan Recall: Patients Taking Valsartan at Risk of Developing Cancer” yet. Be the first to speak your mind!

Leave a Reply